tradingkey.logo

Journey Medical Corp

DERM

7.300USD

+0.030+0.41%
收盘 09/19, 16:00美东报价延迟15分钟
171.34M总市值
亏损市盈率 TTM

Journey Medical Corp

7.300

+0.030+0.41%
关于 Journey Medical Corp 公司
Journey Medical Corporation 是一家商业阶段制药公司。该公司专注于开发和商业化用于治疗皮肤病的药品。其产品组合包括七种品牌和两种授权仿制处方药,用于治疗皮肤病,这些药物均在美国销售。其销售的产品已获得美国食品药品管理局 (FDA) 的批准,包括 Qbrexza、Accutane、Amzeeq、Zilxi、Exelderm 乳膏和溶液、Targadox 和 Luxamend。该公司销售两种授权仿制产品,包括硝酸硫康唑乳膏和溶液以及盐酸多西环素速释片 50mg。Qbrexza 是一种用于治疗原发性腋窝多汗症的药用布巾。Accutane 是一种口服异维甲酸药物,用于治疗严重的顽固性结节性痤疮。Targadox 是一种口服强力霉素药物,用于严重痤疮的辅助治疗。
公司简介
公司代码DERM
公司名称Journey Medical Corp
上市日期Nov 12, 2021
CEOMr. Claude Maraoui
员工数量41
证券类型Ordinary Share
年结日Nov 12
公司地址9237 E Via De Ventura Blvd., Suite 105
城市SCOTTSDALE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编85258
电话14804346670
网址https://journeymedicalcorp.com/
公司代码DERM
上市日期Nov 12, 2021
CEOMr. Claude Maraoui
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+53.80%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
业务USD
名称
营收
占比
Qbrexa
5.16M
39.28%
Accutane
3.65M
27.82%
Emrosi
2.07M
15.75%
Amzeeq
1.10M
8.37%
Other branded revenue
727.00K
5.53%
Zilxi
426.00K
3.24%
地区USD
名称
营收
占比
United States
13.14M
100.00%
业务
地区
业务USD
名称
营收
占比
Qbrexa
5.16M
39.28%
Accutane
3.65M
27.82%
Emrosi
2.07M
15.75%
Amzeeq
1.10M
8.37%
Other branded revenue
727.00K
5.53%
Zilxi
426.00K
3.24%
股东统计
更新时间: 9月9日 周二
更新时间: 9月9日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fortress Biotech Inc
16.55%
Maraoui (Claude)
10.15%
Tang Capital Management, LLC
9.13%
Wasatch Global Investors Inc
5.67%
The Vanguard Group, Inc.
2.78%
其他
55.72%
持股股东
持股股东
占比
Fortress Biotech Inc
16.55%
Maraoui (Claude)
10.15%
Tang Capital Management, LLC
9.13%
Wasatch Global Investors Inc
5.67%
The Vanguard Group, Inc.
2.78%
其他
55.72%
股东类型
持股股东
占比
Corporation
16.55%
Individual Investor
16.12%
Hedge Fund
10.86%
Investment Advisor/Hedge Fund
10.28%
Investment Advisor
9.95%
Insurance Company
0.89%
Research Firm
0.32%
Private Equity
0.16%
Pension Fund
0.07%
其他
34.81%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
93
10.34M
59.77%
+53.87K
2025Q1
89
9.75M
61.79%
-68.70K
2024Q4
83
8.33M
55.97%
-821.12K
2024Q3
84
6.72M
45.26%
-1.40M
2024Q2
79
7.11M
49.43%
-621.27K
2024Q1
70
6.34M
49.52%
-781.26K
2023Q4
68
5.80M
46.63%
-1.25M
2023Q3
54
6.63M
53.88%
+189.20K
2023Q2
50
5.90M
48.59%
-532.43K
2023Q1
47
7.46M
63.41%
-218.78K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fortress Biotech Inc
3.36M
19.43%
--
--
Apr 14, 2025
Maraoui (Claude)
821.75K
4.75%
+49.28K
+6.38%
Jun 17, 2025
Tang Capital Management, LLC
1.85M
10.72%
+129.03K
+7.48%
Mar 31, 2025
Wasatch Global Investors Inc
930.60K
5.38%
+930.60K
--
Mar 31, 2025
The Vanguard Group, Inc.
372.26K
2.15%
+47.09K
+14.48%
Mar 31, 2025
Rosenwald (Lindsay A)
320.71K
1.85%
-9.73K
-2.94%
Apr 14, 2025
Alloush (Ramsey)
316.68K
1.83%
+46.86K
+17.37%
Jun 17, 2025
Geode Capital Management, L.L.C.
113.74K
0.66%
+4.53K
+4.14%
Mar 31, 2025
Renaissance Technologies LLC
238.00K
1.38%
+2.00K
+0.85%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
KeyAI